Abstract. Long non-coding RNAs (lncRNAs) are untranslated transcripts with longer than 200 nucleotides (nt), which possess many of the structural characteristics of mRNAs, including a poly A tail, 5'-capping, and a promoter structure, but no conserved open reading frame. Moreover, lncRNA expression patterns change during differentiation and exhibit a variety of splicing patterns. Many lncRNAs are expressed at specific times and in specific tissues during development. It has been proposed that lncRNAs are involved in the epigenetic regulation of coding genes, and thus exert a powerful effect on a number of physiological and pathological processes, including the pathogenesis of many human rare diseases.
Contents
IntroductionAt present, five classes of long non-coding RNAs (lncRNAs) are known: anti-sense lncRNAs, intronic non-coding RNAs, large intergenic non-coding RNAs (lincRNAs), promoter-associated lncRNAs, and untranslated region (UTR)-associated lncRNAs (1). These lncRNAs are involved in a variety of vital regulation processes, including X-chromosome inactivation, genomic imprinting, chromatin modification, transcriptional activation, transcriptional interference, and nuclear transport, suggesting a possible involvement in diseases (2). lncRNAs are aberrantly expressed in several complex disorders and appear to be directly linked to the incidence of some diseases (3). This review summarizes the potential association between lncRNAs and human rare diseases.
The association between long non-coding RNA and human rare diseasesIn differentiation and development processes, the dysfunction of non-coding RNA often leads to disease. Abnormality of lncRNA might affect DNA methylation, histone modification, and chromatin remodeling in various ways. Moreover, as a precursor of microRNA, lncRNAs play an important role in the initiation and progression of disease. Recent studies (4,5,6,7) have found that C15orf2, H19, Ube3a-as, and DGCR5 are associated with rare diseases (Table I).
Prader-Willi syndromePrader-Willi syndrome (PWS) is a neurogenetic disorder that results from loss of the paternal contribution of a 1.5-Mb imprinted region on the proximal long arm of chromosome 15. PWS is characterized by neonatal muscular hypotonia and failure to thrive, hyperphagia and obesity starting in early childhood, as well as hypogonadism, short stature, small hands and feet, sleep apnea, behavioral problems and mild to moderate mental retardation (8). C15orf2 is a testis-specific gene that maps between NDN and SNURF-SNRPN and is expressed by the two alleles. The novel genes Prader-Willi region non-protein-coding RNA 1 and 2 are located between NDN and C15orf2. PWRN2 is expressed only in testis and is biallelic (4). PWRN1 is biallelically expressed in testis and kidney. Investigation of C15orf2 revealed that this gene is also expressed in the fetal brain but is monoallelic. Therefore,